The Somerset, N.J.-based company plans to give underwriters a 30-day option to buy up to $60 million in additional shares of common stock.
Catalent, which has been on a buying spree in the last year, said it expects to use the offering’s net proceeds to repay a portion of its U.S. dollar-denominated term loans.
The company shelled out $950 million in cash last year to pick up Cook Pharmica, a contract manufacturer that develops biologics-based drug compounds.
The company explained that its Juniper acquisition complements Catalent’s formulation development offerings, bioavailability solutions and clinical-scale oral dose manufacturing capabilities.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.